FDA to Review Arena's Diet Drug, Alkermes' Painkiller Addiction Med

FDA meets to discuss weight-loss drug and painkiller addiction medThe U.S. Food and Drug Administration is going to have a busy day. Two advisory panels will meet to discuss two different drugs on Thursday: Arena Pharmaceuticals' (ARNA) obesity treatment lorcaserin and Alkermes' (ALKS) Vivitrol Opioid for opioid addiction. A third drug -- AstraZeneca's(AZN) blood thinner Brilinta -- faces an approval decision, but that will be delayed.

Arena shares had a rough week, sinking over 46% since Monday after FDA reviewers on Tuesday released an initial analysis raising questions about lorcaserin's safety and effectiveness. Arena shares will be halted Thursday.

Arena's Diet Drug -- Yea or Nay?

In their analysis ahead of the meeting, FDA reviewers raised concerns about cancerous breast tumors, although this was only seen when lorcaserin was tested in rats, not humans. Also of concern were other side effects, such as heart-valve disease, psychiatric and memory problems. In addition to its safety, the drug's effectiveness was also questioned, as it failed to meet one of the agency's efficacy benchmarks for weight loss while meeting a second criteria for effectiveness only "by a slim margin."

Several companies have attempted to create a safe diet drug over the years, but ever since the debacle 13 years ago of combination drug phen-fen, which was linked to heart-valve damage and a rare but deadly lung disease, the FDA has been extra cautious.

While Arena's rival Vivus (VVUS) has already faced the panel and got a "no" vote for its obesity treatment Qnexa, Arena's lorcaserin is seen as the safer of the three recent diet drugs. Orexigen (OREX) is the third. Proponents of lorcaserin say it hasn't demonstrated serious side effects. In fact, after two years of safety data, patients are free from any additional cardiovascular problems, and nearly half of the patients in a study achieved at least 5% weight loss after a year.

But complicating matters further for Arena was the panel's mixed vote on Wednesday regarding Abbott's (ABT) already approved weight-loss pill Meridia. The advisory panel urged tougher action against the controversial drug but split over whether to call for a ban. European regulators have already pulled Meridia from the market.

More Tests Needed for Alkermes Vivitrol Opioid?

Alkermes shares first fell when regulators released their analysis ahead of the panel meeting, but then recovered even as it seemed the panel might ask for another test before voting in favor of expanding the indication of alcoholism drug Vivitrol to treat opiate addiction. Trading in Alkermes shares has been halted Thursday morning.

Vivitrol helped prevent relapse in patients addicted to heroin and painkillers who were trying to stop using drugs in a Russian study, FDA reviewers said. Moreover, there were no major new safety issues. But they questioned whether the small, single study with perhaps a different target population than in the U.S. was sufficient to clear the drug for this use. The agency is scheduled to decide on the supplemental new drug application by Oct. 12.

As for AstraZeneca's ticagrelor, or Brilinta, the company announced the FDA has extended the time to complete its review of the experimental blood thinner by three months to Dec. 16. In July, FDA advisory committee members voted 7 to 1 to recommend the approval of Brilinta in patients with acute coronary syndrome, or blocked arteries.

Brilinta is seen as a potential blockbuster drug for AstraZeneca. The blood thinner market is currently dominated by Plavix from Sanofi-Aventis (SNY) and Bristol-Myers Squibb (BMY). Plavix has total sales of $9.8 billion globally. An international study conducted by AstraZeneca showed that patients taking Brilinta versus Plavix were less likely to experience various heart-related problems.

Oddly enough, however, U.S. patients studied were more likely to report heart problems while taking Brilinta. Brilinta might also eliminate the need for genetic testing. It's currently under regulatory review in the European Union, Canada, and Brazil.

Increase your money and finance knowledge from home

Investing in Startups

The lucrative and risky world of startups.

View Course »

Investment Strategies

What's your investing game plan?

View Course »

Add a Comment

*0 / 3000 Character Maximum


Filter by:

Yes, I agree with the commentors. That panel consists of only 5 people or so and that is not fair. I am sick of doctors handing out dangerous antidepressants to everyone in place of what a patient needs to improve their mood or get rid of pain that is authentic. Antidepressants are to blame for many deaths and I think they should be looked at closely, especially their side effects. If Obama wants the poor Americans to get back to work when they are hungry with lack of money then simply allow some type of energy pill instead of this drinking coffee, etc. When they deny all of these drugs placing strong controls over them it is going to make the underground even worse than it already is. So if he wants income tax forms filed and money flowing they need to lighten up on the controls.

September 16 2010 at 11:54 AM Report abuse +2 rate up rate down Reply

There is no money to be made in curing addiction. The quentessential example is the widespread Methadone program. LSD addictions is just that, drug addiction. But these programs give Methadone, a legal drug issued by drug manufacturers, to "recovering" LSD addicts on a regular basis. Methadone is a controlled substance and is also addictive. This government-approved program simply substitutes addiction to a legal drug for addiction to an illegal substance. Same with, like, Chantix. It helps you stop smoking by giving you a government-approved drug you take on an addictive basis to combat your smoking addiction. The best cure for the problems facing many Americans? A little "pick-me-up" pill. That's right. Instead of all these ridiculous concoctions to fight obesity and all these zombie drugs for depression, give us something to pick us up. A little amphetamine will go a long way. What we need is a little energy, a little motivation, a way to get a little kick besides drinking a quart of strong coffee or wondering if your best bet isn't the local meth lab. We are a drug addicted society. We simply choose to believe otherwise because the drugs we are hooked on are legal and government-approved. And I don't care if it hairlips the Pope, God love him, if I ever get to one of the MANY countries where the peaceful, productive, happy people chew on coca leaves, I'm fixing to eat me a friggin' mouthful!!!

September 16 2010 at 11:25 AM Report abuse +3 rate up rate down Reply
Bill Conklin

I still think the fen-fen thing was overblown. So, a couple of people had heart attacks - isn't that what happens to overweight people? I've been heavy my whole life and the ONLY thing that was working for me was fen-fen. Unfortunately, I got on it right at the end but I was NEVER hungry, felt fantastic, slept well and had more energy. Then they dropped the hammer on it. Here is a new drug and they are talking about breast cancer and stuff and they haven't tested it on humans...they only THINK it might be problematic! Come on people....give us a break.

September 16 2010 at 8:51 AM Report abuse +2 rate up rate down Reply
2 replies to Bill Conklin's comment

I agree. fen-fen worked for me too. My doctor was very vigilent about seeing me while I was on it. I lost weight and felt fantastic too. A lot of those who died had previously undiagnosed heart problems and the pills were blamed when they may not have been a factor. Too bad it is off the market.

September 16 2010 at 2:00 PM Report abuse +1 rate up rate down Reply

I agree. fen-fen worked for me too. My doctor was very vigilent about seeing me while I was on it. I lost weight and felt fantastic too. A lot of those who died had previously undiagnosed heart problems and the pills were blamed when they may not have been a factor. Too bad it is off the market.

September 16 2010 at 2:07 PM Report abuse rate up rate down Reply